Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 64Tacrolimus 55Methotrexate 46Mycophenolic Acid 39Cyclosporine 37fludarabine phosphate 35Busulfan 35Antilymphocyte Serum 32fludarabine 29Sirolimus 26Melphalan 23Peripheral Blood Stem Cell Transplantation 22Radiotherapy 21Methylprednisolone 21Whole-Body Irradiation 19Filgrastim 17thymoglobulin 14Thiotepa 11Stem Cell Transplantation 10Rituximab 10ruxolitinib 9Granulocyte Colony-Stimulating Factor 9Prednisone 7Hematopoietic Stem Cell Transplantation 7Etoposide 7Cord Blood Stem Cell Transplantation 7Alemtuzumab 7Pentostatin 6Cytarabine 6Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Graft vs Host Disease × belumosudil × Clear all
NCT07006506 2026-04-13

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
46 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡